Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 1:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 9,234 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute GVH Disease Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Explorations of the Benefits of the ZeroG TRiP System to Improve Balance in Patients Following Stroke

NCT04919161
View directory record Official record
Conditions
Stroke, Balance; Distorted
Interventions
Body weight support system control group, Body weight support system with balance perturbations
Device
Lead sponsor
Gaylord Hospital, Inc
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 9, 2026, 1:47 PM EDT
Terminated Phase 1 Interventional

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

NCT02203773
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
Interventions
Posaconazole, ABT-199, Decitabine, Azacitidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
60 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
13
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 9, 2026, 1:47 PM EDT
Terminated Phase 1 Interventional

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL

NCT04049383
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia
Interventions
CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 9, 2026, 1:47 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis

NCT06993454
View directory record Official record
Conditions
Type 2 Diabetes, Hepatic Steatosis
Interventions
Magnetic Resonance Liver Assessment, Bike Exercise VO2max, DEXA
Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
25 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 9, 2026, 1:47 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

NCT06284486
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Venetoclax, Revumenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 9, 2026, 1:47 PM EDT
Completed Not applicable Interventional

Wiser Choices in Acute Myocardial Infarction

NCT00888537
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
AMI Choice Decision Aid, Usual Care
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 9, 2026, 1:47 PM EDT
Terminated No phase listed Observational

Post-Market Observation Study of Intra-renal Drug Delivery (PROVIDE)

NCT01064895
View directory record Official record
Conditions
Acute Kidney Injury, Acute Renal Failure, Renal Failure Chronic Contrast Induced, Chronic Kidney Disease
Interventions
Benephit catheter for Targeted Renal Therapy
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Miami, Florida • Miramar, Florida • Blackfoot, Idaho + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Oct 9, 2026, 1:47 PM EDT
Not listed No phase listed Observational

Vincristine PK and PD in the AYA Population Compared to Younger Children

NCT02360930
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic, Leukemia
Interventions
Not listed
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 24 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 9, 2026, 1:47 PM EDT
Completed Not applicable Interventional Results available

Non-Pharmacological Interventions on Sleep in Post-Acute Rehabilitation

NCT00333619
View directory record Official record
Conditions
Sleep Disorders
Interventions
Nonpharmacological sleep intervention, Active control
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Sepulveda, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 9, 2026, 1:47 PM EDT
Completed Phase 2 Interventional

Intensified Post Remission Therapy Containing PEG-Asparaginase

NCT00184041
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 9, 2026, 1:47 PM EDT
Terminated Phase 4 Interventional Results available

Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit

NCT03168529
View directory record Official record
Conditions
Heart Failure
Interventions
Ivabradine, Placebo
Drug
Lead sponsor
Phillip Levy
Other
Eligibility
19 Years to 89 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 9, 2026, 1:47 PM EDT
Completed Not applicable Interventional

A Comparison of Early Mobilization Versus Traditional Treatment for Acute Ankle Sprains.

NCT01134653
View directory record Official record
Conditions
Ankle Sprain
Interventions
Jump Stretch
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
8 Years to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 9, 2026, 1:47 PM EDT
Recruiting Not applicable Interventional

RCT of Pain Perception With Fast and Slow Tenaculum Application

NCT05458037
View directory record Official record
Conditions
Pain, Acute, Pain, Procedural
Interventions
Speed of tenaculum application
Procedure
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 9, 2026, 1:47 PM EDT
Completed Phase 2 Interventional Results available

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

NCT01350245
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Biphenotypic Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Plasma Cell Neoplasms, Lymphoma, Hodgkin's Disease, Aplastic Anemia
Interventions
Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide, Mycophenolate Mofetil (MMF), Tacrolimus, Hematopoietic stem cell transplantation (HSCT)
Radiation · Biological · Drug + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 9, 2026, 1:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

NCT01866839
View directory record Official record
Conditions
MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder, Lymphoma, Non-Hodgkin, ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia
Interventions
Graft Manipulation (CD34+ Selection)
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 9, 2026, 1:47 PM EDT
Completed Phase 3 Interventional Results available

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

NCT00439777
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin overlapping with and followed by VKA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
23
States / cities
Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 9, 2026, 1:47 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

NCT01732757
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
10 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 9, 2026, 1:47 PM EDT
Recruiting Not applicable Interventional

Clinical Decision Support Tool in PARDS Pilot Study

NCT04068012
View directory record Official record
Conditions
Ventilation Therapy; Complications, Ventilator-Induced Lung Injury, Ards
Interventions
Ventilator protocol
Other
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Month to 18 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
Chicago, Illinois • Indianapolis, Indiana • Hershey, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 9, 2026, 1:47 PM EDT
Withdrawn Phase 2 Interventional

Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD

NCT05333029
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP)
Biological
Lead sponsor
Molly Gallogly
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 9, 2026, 1:47 PM EDT
Completed Phase 2 Interventional

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

NCT01563445
View directory record Official record
Conditions
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions
activated recombinant human factor VII, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 9, 2026, 1:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers

NCT00899795
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
cytogenetic analysis, fluorescence in situ hybridization, flow cytometry, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
5 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 9, 2026, 1:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

In-Field Detection of Intracranial Pressure

NCT04515212
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Optic Nerve Ultrasounds
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 99 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 9, 2026, 1:47 PM EDT
Completed Phase 3 Interventional Results available

Perioperative Pregabalin in Ureteroscopy: a Pilot

NCT03927781
View directory record Official record
Conditions
Nephrolithiasis, Urolithiasis, Perioperative/Postoperative Complications, Pain, Postoperative, Pain, Acute, Anesthesia, Urologic Diseases, Anesthesia Morbidity
Interventions
Pregabalin 300mg
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 9, 2026, 1:47 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy

NCT05868122
View directory record Official record
Conditions
Pain
Interventions
Acetaminophen/Naproxen Sodium Fixed Combination, Placebo
Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
16 Years to 65 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
New Providence, New Jersey • Bellaire, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 9, 2026, 1:47 PM EDT